Drug Database
AN

antithrombin III (Atenotiv / ATenativ / ATnativ)

✓ Approved

Pfizer, Inc. · SERPINC1 · 细胞治疗

什么是 antithrombin III?

antithrombin III 是一种细胞治疗,由Pfizer, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Atenotiv, ATenativ, ATnativ
公司Pfizer, Inc.
药物类别细胞治疗
分子靶点SERPINC1
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

antithrombin III 作用于 1 个分子靶点:

SERPINC1serpin family C member 1 (ATIII, AT3D)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

antithrombin III 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved
Vascular disordersThrombosis✓ Approved
Surgical and medical proceduresAdjuvant therapy✓ Approved

相关研究文献

PubMedBMC gastroenterology2026-11-17

Reduced antithrombin III and in-hospital organ failure in hypertriglyceridemia-associated acute pancreatitis with elevated D-dimer: a retrospective cohort study.

Wu Guotong G, Qiao Yulong Y, Pan Zhengyu Z, Wang Xin X et al.

D-dimer is widely used to reflect coagulation and fibrinolytic activation in acute pancreatitis, but outcomes vary among patients with elevated D-dimer. Reduced antithrombin III (AT-III) may indicate diminished endogenous anticoagulant reserve during systemic coagulation activation. We assessed the association between reduced AT-III and organ failure during hospitalization among patients with hypertriglyceridemia-associated acute pancreatitis (HTG-AP) and elevated D-dimer. This retrospective cohort study included hospitalized patients with HTG-AP from October 2020 to November 2025. D-dimer elevation was defined as > 0.55 mg/L FEU and AT-III reduction as < 75%, according to local laboratory reference ranges. The primary outcome was organ failure during hospitalization. Patients admitted in 2020-2023 and 2024-2025 were described as the earlier and later admission cohorts, respectively. Among patients with elevated D-dimer, binary logistic regression was used to evaluate the association between reduced AT-III and organ failure. The main model adjusted for age, sex, ln(D-dimer), ln(triglycerides), and ln(time from symptom onset to admission + 1). Of 959 patients with complete admission D-dimer and AT-III data, 79 (8.2%) had organ failure during hospitalization. Among 418 patients with elevated D-dimer, organ failure occurred in 44 of 151 patients (29.1%) with reduced AT-III and in 25 of 267 patients (9.4%) with preserved AT-III. After adjustment including continuous ln(D-dimer), reduced AT-III remained associated with organ failure (odds ratio [OR] 3.30, 95% confidence interval [CI] 1.86-5.85; P < 0.001). The corresponding observed event rates in the earlier and later admission cohorts were 27.8% and 31.5% with reduced AT-III, compared with 9.5% and 9.2% with preserved AT-III. Among patients with HTG-AP and elevated D-dimer, reduced AT-III was associated with a higher observed frequency of organ failure during hospitalization. These findings support further evaluation of AT-III as a routinely available coagulation marker in HTG-AP.

PMID 43040483
阅读全文 →
PubMedPakistan journal of medical sciences2026-11-17

A clinically applicable nomogram for predicting recurrent spontaneous abortion using coagulation and autoimmune markers.

Xie Yuedan Y, Huang Pingping P, Gao Xiaofen X, Chen Xuzhen X et al.

To develop and validate a risk prediction model for recurrent spontaneous abortion (RSA) by integrating thrombus markers with anticardiolipin antibody (ACA) and antinuclear antibody (ANA) indicators. Clinical data of 159 RSA patients (June 2021-June 2022) and 178 healthy controls from Rui'an People's Hospital were retrospectively analyzed. Clinical and laboratory parameters, including coagulation markers and autoantibodies, were analysed. Predictor selection was performed using a consensus approach combining univariate logistic regression, least absolute shrinkage and selection operator (LASSO) regression, and Random Forest feature importance. Multivariate logistic regression was subsequently used to identify independent predictors. Machine learning models were developed and evaluated using a 70:30 train-test split with 5-fold cross-validation. Model performance was assessed using area under the curve (AUC), sensitivity, specificity, and calibration metrics. Six independent predictors were identified: protein S, protein C, antithrombin-III (AT-III), fibrinogen (FIB), ACA-IgG, and ANA status. Reduced levels of natural anticoagulants (protein S, protein C, and AT-III) were associated with increased RSA risk, whereas elevated FIB and ACA-IgG levels and ANA positivity were significant risk factors. The Random Forest model demonstrated the best performance with an AUC of 0.765 (95% confidence interval [CI]: 0.665-0.851), sensitivity of 60.4%, and specificity of 75.9%. The model showed good calibration (Brier score 0.199). A nomogram based on logistic regression achieved an AUC of 0.700. A combined biomarker model integrating coagulation and immune parameters provides moderate-to-good predictive performance for RSA. This clinically applicable tool may facilitate early risk stratification and individualized management, although external validation is required before routine implementation.

PMID 43041959
阅读全文 →
PubMedAdvanced materials (Deerfield Beach, Fla.)2026-11-17

Luminescent and Stable Eu(III) Complex Nanocrystals: A Class of Eu(III) Emitters Toward Amine/Ammonia.

Wang Yu Y, Li Jie J, Long Haoyang H, Dai Ruiyan R et al.

Eu(III) complexes exhibit highly efficient luminescence, while their emissions are significantly sensitive to amine/ammonia-induced quenching. Herein, we report a class of Eu(III) complex nanocrystals in which aliphatic amines serve as structural regulators to construct highly luminescent and stable ultrasmall Eu(III) emitters. The addition of aliphatic amines enables the originally insoluble complexes to be dissolved in n-hexane, producing Eu(III) complex nanocrystal solutions. The primary- and secondary-amine based Eu(btfa)3PBI nanocrystal solutions showed photoluminescence quantum yields (PLQYs) reaching 24%-36% and 30%-37%, respectively. In a sharp contrast, the complex's luminescence was completely or substantially quenched when dissolved directly in primary or secondary amine liquids, with PLQYs decreasing to 0 or 0.0%-1.2%. The significantly suppressed quenching upon nanocrystal formation originated from the substantial reduction of vibrationally induced nonradiative decays, which was further supported by the low quenching constants toward amines. The nanocrystal's emission was further enhanced upon using the tertiary amines. A remarkable PLQY of 64% was obtained for tri-n-decylamine based Eu(dbm)3dmbipy nanocrystals. The nanocrystal solutions exhibited excellent stability, with their PLQYs well retained after 10 h of ambient storage or continuous irradiation with 365 nm UV light. Furthermore, proof-of-concept experiments demonstrated the potential application of nanocrystal solids as amine/ammonia-resistant warning labels.

PMID 43042862
阅读全文 →
PubMedAnnals of surgical oncology2026-11-17

ASO Author Reflections: Can Pathological Invasion Status Help Select Patients for Adjuvant Chemotherapy in Stage II-III Non-small Cell Lung Cancer?

Hirai Yuya Y, Mimae Takahiro T, Okada Morihito M

PMID 43040159
阅读全文 →
PubMedDermatology online journal2026-11-17

Phase II and III biologics and small molecules for chronic spontaneous urticaria: A systematic review.

Kadu Priya P, Huang Chenan A CA, Ulfers Audrey A, Jorizzo Joseph L JL

Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that requires chronic therapy and impairs patients' quality of life. Despite first-line antihistamine and second-line omalizumab therapy, up to 30% of patients remain symptomatic. Novel therapies for CSU are needed to address this therapeutic gap. To determine the efficacy and safety of phase II and III biologics and small molecules in chronic spontaneous urticaria. A systematic review was conducted using PRISMA guidelines to include randomized, double-blind, placebo-controlled clinical trials evaluating phase II and phase III biologics and small molecules for CSU. PubMed, ClinicalTrials.gov, Embase, and Scopus databases were searched. Bruton tyrosine kinase (BTK) inhibitors, including remibrutinib, fenebrutinib, and rilzabrutinib, are fast-acting, oral medications with a favorable safety and efficacy in CSU and greater potency in type IIb autoimmune urticaria. Ligelizumab and dupilumab represent injectable biologics with intermittent (biweekly to monthly) administration. Quilizumab, canakinumab, tezepelumab, and benralizumab are not beneficial in CSU. BTK inhibitors are efficacious in CSU and may be superior to omalizumab for type IIb autoimmune urticaria, where disease control is often delayed and limited with anti-IgE agents. Ligelizumab and dupilumab are safe and effective alternatives to omalizumab for antihistamine-resistant CSU.

PMID 43040805
阅读全文 →
PubMedBlood cancer journal2026-11-17

Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402).

Sborov Douglas W DW, Mahindra Anuj K AK, Suman Vera J VJ, Manasanch Elisabet Esteve EE et al.

PMID 43039885
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多antithrombin III